The role of epigenetics and long noncoding RNA MIAT in neuroendocrine prostate cancer.

Neuroendocrine prostate cancer (NEPC) is the most lethal prostatic neoplasm. NEPC is thought to originate from the transdifferentiation of AR-positive adenocarcinoma cells. We have previously shown that an epigenetic/noncoding interactome (ENI) orchestrates cancer cells' plasticity, thereby allowing the emergence of metastatic, drug-resistant neoplasms.

The primary objective of this manuscript is to discuss evidence indicating that some components of the ENI (Polycomb genes, miRNAs) play a key role in NEPC initiation and progression. Long noncoding RNAs represent vast and largely unexplored component of the ENI. Their role in NEPC has not been investigated. We show preliminary evidence indicating that a lncRNA (MIAT) is selectively upregulated in NEPCs and might interact with Polycomb genes. Our results indicate that long noncoding RNAs can be exploited as new biomarkers and therapeutic targets for NEPC.

Epigenomics. 2016 Apr 20 [Epub ahead of print]

Francesco Crea, Erik Venalainen, Xinpei Ci, Hongwei Cheng, Larissa Pikor, Abhijit Parolia, Hui Xue, Nur Ridzwan Nur Saidy, Dong Lin, Wan Lam, Colin Collins, Yuzhuo Wang

Experimental Therapeutics, BC Cancer Agency Cancer Research Centre, Vancouver, BC, Canada., Experimental Therapeutics, BC Cancer Agency Cancer Research Centre, Vancouver, BC, Canada., Experimental Therapeutics, BC Cancer Agency Cancer Research Centre, Vancouver, BC, Canada., Experimental Therapeutics, BC Cancer Agency Cancer Research Centre, Vancouver, BC, Canada., Genetics Unit, Integrative Oncology, BC Cancer Agency Cancer Research Centre, Vancouver, BC, Canada., Experimental Therapeutics, BC Cancer Agency Cancer Research Centre, Vancouver, BC, Canada., Experimental Therapeutics, BC Cancer Agency Cancer Research Centre, Vancouver, BC, Canada., Experimental Therapeutics, BC Cancer Agency Cancer Research Centre, Vancouver, BC, Canada., Experimental Therapeutics, BC Cancer Agency Cancer Research Centre, Vancouver, BC, Canada., Genetics Unit, Integrative Oncology, BC Cancer Agency Cancer Research Centre, Vancouver, BC, Canada., Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada., Experimental Therapeutics, BC Cancer Agency Cancer Research Centre, Vancouver, BC, Canada.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe